Calithera Biosciences, an early-stage biotech developing a drug platform for tumor metabolism and immunology, filed on Monday with the SEC to raise up to $80 million in an initial public offering.
The San Francisco, CA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol CALA. Calithera Biosciences initially filed confidentially on July 25, 2014. Citi, Leerink Partners, Wells Fargo Securities and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
